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antibodies to the SIV Env differ from the antibody responses to
the HIV-1 Env. Thus, NHP vaccine studies may require inclusion
of HIV-1 envelope sequences, instead of SIV envelope, to accu-
rately reﬂect antibody speciﬁcities induced by HIV-1 vaccination
in human clinical trials.
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Background: Recent studies in mice and macaques demon-
strated generation of higher frequency and better quality
memory CD8 T cells by inhibiting the mTOR pathway using
rapamycin. In this study, we tested the effect of rapamycin on
the immunogenicity and efﬁcacy of a DNA/MVA SIV vaccine
in rhesus macaques.
Methods: Macaques were primed with a DNA/SIV vaccine on
weeks 0 and 8, and boosted with a MVA/SIV vaccine on weeks 16
and 24 in the absence (DM) or presence of rapamycin either during
MVA boosts or during primes and boosts. Rapamycin treatment
was given for a period of 32 days starting from day -3 of each
immunizationwhere used. Macaques were challengedwith SIV251
intrarectally at about 21–24 weeks after the ﬁnal MVA boost.
Results: Rapamycin treatment did not increase the magnitude
but reduced contraction of effector CD8 T cell response that re-
sulted in higher frequencies of SIV-speciﬁc memory CD8 T cells
with enhanced quality as determined by higher expression of
CCR7 and BCl-2 ex vivo and higher proliferative capacity in vitro.
Rapamycin treatment did not signiﬁcantly alter the memory CD4
T cell response. Post SIV251 infection, rapamycin-treated ma-
caques demonstrated a marked expansion of SIV-speciﬁc CD8 T
cells reaching up to 50% in blood and 25% in gut and this en-
hanced expansion in rapamycin-treated groups was associated
with a markedly lower (2-logs compared to unvaccinated and 1-
log compared to DM) set-point viral loads, better preservation of
central memory T cells in blood and enhanced survival compared
to unvaccinated and DM-vaccinated macaques.
Conclusion: Inhibiting mTOR pathway during MVA boosts of a
DNA/MVA vaccine regimen enhances the functional quality of
vaccine-elicited memory CD8 T cell response that is capable of
markedly restricting a highly pathogenic SIV replication.
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Background: Varicella Zoster virus (VZV) is a persistently rep-
licating virus with the potential to deliver life-long immunity in
an HIV vaccine setting. As a recombinant vaccine vector, the
ability to self-boost may overcome the limited capacity of pox-
and adenoviral vectors to generate long-lived immunogenicity.
Methods: We describe a comprehensive preclinical non-human
primate challenge trial with recombinant VZV-SIV constructs
expressing codon-optimized and safety augmented antigenic
targets from SIV as candidate prophylactic HIV vaccines. As a
strict evaluation of our approach, a cohort of MHC-typed cyno-
molgus macaques were administered only a single vaccination
with VZV-SIV vaccine or vector alone, and subsequently chal-
lenged intra-rectally using a weekly low-dose exposure to highly
pathogenic SIV.
Results: Vaccine-induced durable humoral and cellular immune
responses were observed with evidence to suggest VZV replica-
tion and subsequent reactivation driving progressive increases in
anti-VZV IgG titers. There was no signiﬁcant difference in SIV
acquisition rates or challenge doses to infection between vaccine
and control groups over the course of multiple low-dose mucosal
challenges. Importantly, the vaccine group showed lower peak
and set point viral loads (VL) with a subset of vaccinees (*35%)
with persistent undetectable VL over 1.5 yrs of follow-up.We saw
no evidence of accelerated disease course or increased SIV repli-
cation in vaccinees.
Conclusion: A single dose of human VZV-based SIV vaccines
was sufﬁcient to provide substantial beneﬁt to vaccinees with
apparent early disease modiﬁcation and preliminary evidence to
suggest a similar capacity to induce viral clearance as recently
demonstrated by Louis Picker’s related RhCMV-based approach.
Future work will be directed to determine the extent of this SIV
clearance with subsequent NHP trials designed to augment the
immunogenicity and capacity of this approach. The well docu-
mented clinical and safety evaluations of VZV vaccines in hu-
mans, provides a substantial advantage in developing this
platform for human clinical trials.
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Background: Following infection by HIV-1, the host immune
response is unable to clear the virus due to a variety of factors,
including rapid viral mutation and the establishment of latent
reservoirs. The only target of neutralizing antibodies is the tri-
meric envelope (Env) spike complex, but HIV-1 can usually evade
anti-spike antibodies due to rapid mutation of its two spike gly-
coproteins, gp120 and gp41, and structural features that allow the
spike to hide conserved epitopes. Efforts to design an effective
antibody-based vaccine against HIV-1 would beneﬁt from un-
derstanding how germ-line B-cell receptors recognize the gp120/
gp41 envelope spike. Recently isolated from several infected in-
dividuals, potent VRC01-like (PVL) HIV-1 antibodies derived
from the VH1–2*02 germ-line allele target the CD4 binding site on
gp120. These antibodies have unprecedented potency and
breadth for HIV-1 neutralization and some protect against HIV-1
infection in animal models. Since the VH1–2*02 germ-line allele is
present in up to 95% of the population, it may be possible to elicit
by vaccination similar CD4 binding site antibodies in other
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individuals. VH1–2*02 germ-line B-cell receptor interactions with
gp120 were uncharacterized, which was a bottleneck for de-
signing immunogens to elicit PVL antibodies.
Methods:We determined the structures of a VH1–2*02 germ-line
antibody alone and a germ-line heavy chain/mature light chain
chimeric antibody complexed with gp120 by X-ray crystallogra-
phy and characterized them through surface plasmon resonance
and neutralization experiments.
Results: VH1–2*02 residues make extensive contacts with the
gp120 outer domain, including all PVL-signature and CD4-
mimicry interactions, but not critical CDRH3 contacts with the
gp120 inner domain and bridging sheet that are responsible for
the improved potency of NIH45–46 over closely-related clonal
variants, such as VRC01.
Conclusion:Our results provide insight into initial recognition of
HIV-1 by VH1–2*02 germ-line B-cell receptors and may facilitate
the design of immunogens tailored to engage and stimulate broad
and potent CD4-binding site antibodies.
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Background: Approximately 20% of individuals infected with
HIV-1 develop neutralizing antibodies that are cross-reactive
with a variety of HIV-1 strains. These antibodies generally exhibit
extensive afﬁnity maturation and are slow to appear. Antibodies
targeted against the V1/V2 region of Env display lower levels of
somatic mutation than those targeting other sites of vulnerability
and are among the most frequently elicited. Comprehensive
analysis of B cell ontogeny of effective V1/V2 antibodies would
provide valuable insight into vaccine development aimed at eli-
citing this class of antibody.
Methods: Broadly-neutralizing V1/V2-directed antibodies iso-
lated from donor CAP256 at various time points following in-
fection were isolated, and evolution of antibody development
was longitudinally analyzed through deep sequencing and
structural characterization.
Results: Here we present crystal structures of the antigen-binding
fragments from several V1/V2-directed antibodies isolated from
donor CAP256. The antibodies contain long heavy chain 3rd com-
plementary determining regions (CDR H3)s, a common feature
among V1/V2-directed antibodies. The structures reveal a disulﬁde
bondat the base of an extendedCDRH3 loopand show that tyrosine
sulfation contributes to a negatively charged surface extended away
from the framework of the Fab. Deep sequencing data reveal that the
length of the CDRH3 is the result of a recombination event and does
not extend over time, however speciﬁc features of the mature loop
such as the disulﬁde bond are not found early in the lineage.
Conclusion: Combinatorial studies with structural characteriza-
tion and deep sequencing reveal paths to the development of po-
tent and broad V1/V2 directed antibodies. While some structural
components appear immediately such as the longCDRH3, afﬁnity
maturation plays an important role in stabilizing speciﬁc features.
The ontogeny of the antibodies presented here reveal that breadth
can be achieved rapidly and extensive afﬁnity maturation is not a
necessary feature of broadly neautralizing HIV-1 antibodies.
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Background: CAP256, an HIV-1 subtype C superinfected indi-
vidual, developed potent broadly cross-neutralizing (BCN) V2
plasmaantibodies thatwere critically dependent onR166 andK169.
Eleven related BCNmAbs targeting V2 have recently been isolated
from this individual after 30 months post-infection (p.i.). Here we
investigated the relationship between these mAbs, longitudinal
CAP256 viruses and previously characterized escape variants.
Methods:CAP256primary transmitted/founder (t/f) (N160 glycan -),
superinfecting t/f (N160 glycan + ) and 6-, 12-, 21- and 39-month
viruses were tested for neutralization by the 11 mAbs. The role of
escape mutations at positions 160–171 in V2 and 437 in C4 was
investigated using 15 autologous mutants and 3 chimeric viruses.
Results:While the primary t/fwas only neutralized by 1mAb, all
11 mAbs potently neutralized the superinfecting t/f. All mAbs
were unable to neutralize the 21- and 39-month viruses. mAbs
showed differential dependence on individual V2 mutations,
however the neutralizing activity of all mAbs was abrogated by
R166S or K169E mutations. Deleting the N160 glycan only
slightly affected the neutralizing capabilities of each mAb. Fi-
nally, a sensitive V1V2 chimeric virus was made resistant to all
the mAbs through a P437A mutation in C4.
Conclusion: The potent neutralization of the superinfecting t/f
but not the primary t/f by all mAbs suggested that the super-
infecting t/f was responsible for eliciting these BCN antibodies.
The inability of these mAbs (isolated after 30 months p.i.) to
neutralize autologous clones after 21 months p.i. suggests they
arose before this time point and that this memory B cell family
persisted despite viral escape. The presence of circulating viruses
with and without the N160 glycan after superinfection explains
the independence of the mAbs on this glycan. The drastic effect of
the P437A mutation on mAb activity indicates that in the context
of the envelope trimer, C4 may modulate V2 conformation.
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